Compare CODA & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CODA | ANIX |
|---|---|---|
| Founded | 1994 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 114.7M | 114.0M |
| IPO Year | 2007 | 2013 |
| Metric | CODA | ANIX |
|---|---|---|
| Price | $10.79 | $2.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.67 |
| AVG Volume (30 Days) | 110.0K | ★ 352.7K |
| Earning Date | 06-15-2026 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 15.62 | 12.82 |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $20,316,161.00 | $210,000.00 |
| Revenue This Year | $18.28 | N/A |
| Revenue Next Year | $12.62 | N/A |
| P/E Ratio | $29.75 | ★ N/A |
| Revenue Growth | ★ 4.98 | N/A |
| 52 Week Low | $7.80 | $2.32 |
| 52 Week High | $18.00 | $5.46 |
| Indicator | CODA | ANIX |
|---|---|---|
| Relative Strength Index (RSI) | 57.42 | 38.62 |
| Support Level | $9.82 | $2.66 |
| Resistance Level | $12.24 | $3.09 |
| Average True Range (ATR) | 0.39 | 0.16 |
| MACD | 0.05 | 0.00 |
| Stochastic Oscillator | 66.47 | 31.25 |
Coda Octopus Group Inc develops underwater technologies and equipment for imaging, mapping defense, and survey applications. The company operates in three distinct business segments: the Marine Technology business, Acoustic Sensors and Material Business and the Defense Engineering Services Business. Its geographical segments are the Americas, Europe, Australia/Asia, and the Middle East/Africa. The majority of revenue is derived from the Products segment.
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.